ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results

✍ Scribed by G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G.J. Peters; W.J.F. van der Vijgh; R. Smith; A. Fandi; S. Averbuch

• Book ID: 117657964
• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 338 KB
• Volume: 37
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(01)80594-3